Stéphane (PharmD; PhD; MBA) founded Vetbiobank in anticipation of the growing demand in the animal health market for therapeutic innovation. He invested his expertise in the field of human neonatal stem cells and built a team of passionate collaborators to create a cutting edge and respected pharmaceutical company, able to provide vets with affordable, ready-to-use cell-based medicines to conveniently treat important inflammatory diseases

Nathalie holds an MSc in Biotechnology from the University of Lyon and a PhD from the Catholic University of Rome.
10+ years of research experience with two pending patents and is the first author of two articles on equine and canine stem-cells published in scientific journals. At Vetbiobank, she leads the R&D and Quality Control teams.

Harald (PharmD) invests in Vetbiobank his 25-years of experience in developing biomanufacturing strategies for human cell-based drugs. He is in charge of the industrial scaling up of our process in a designed-by-cost fashion. His expertise in the Human ATMP2 field is a key asset in order to meet all GMP and pharmaceutical requirements for market approval. He leads the GMP compliant Qual. Managt. System and acts as the deputy qualified person

Nadia holds an MBA in Marketing, Strategy and finance from the EM Lyon Business School.
International executive with 15 years of experience at top AH companies and start-ups. Strong expertise focused on international sales and marketing. Since joining Vetbiobank, she has developed strategic collaborations with industry partners and contributed to the fundraising operations.